Inflammatory Ly6C<sup>hi</sup> monocytes and their conversion to M2 macrophages drive atherosclerosis regression

Karishma Rahman, … , P’ng Loke, Edward A. Fisher


Atherosclerosis is a chronic inflammatory disease, and developing therapies to promote its regression is an important clinical goal. We previously established that atherosclerosis regression is characterized by an overall decrease in plaque macrophages and enrichment in markers of alternatively activated M2 macrophages. We have now investigated the origin and functional requirement for M2 macrophages in regression in normolipidemic mice that received transplants of atherosclerotic aortic segments. We compared plaque regression in WT normolipidemic recipients and those deficient in chemokine receptors necessary to recruit inflammatory Ly6C<sup>hi</sup> (Ccr2<sup>−/−</sup> or Cx3cr1<sup>−/−</sup>) or patrolling Ly6C<sup>lo</sup> (Ccr5<sup>−/−</sup>) monocytes. Atherosclerotic plaques transplanted into WT or Ccr5<sup>−/−</sup> recipients showed reduced macrophage content and increased M2 markers consistent with plaque regression, whereas plaques transplanted into Ccr2<sup>−/−</sup> or Cx3cr1<sup>−/−</sup> recipients lacked this regression signature. The requirement of recipient Ly6C<sup>hi</sup> monocyte recruitment was confirmed in cell trafficking studies. Fate-mapping and single-cell RNA sequencing studies also showed that M2-like macrophages were derived from newly recruited monocytes. Furthermore, we used recipient mice deficient in STAT6 to demonstrate a requirement for this critical component of M2 polarization in atherosclerosis regression. Collectively, these results suggest that continued recruitment of Ly6C<sup>hi</sup> inflammatory monocytes and their STAT6-dependent polarization to the M2 state are required for resolution of atherosclerotic inflammation and plaque regression.

Find the latest version:

http://jci.me/75005/pdf
Inflammatory Ly6\textsuperscript{Ch} monocytes and their conversion to M2 macrophages drive atherosclerosis regression

Karishma Rahman,\textsuperscript{1} Yuliya Vengrenyuk,\textsuperscript{2} Stephen A. Ramsey,\textsuperscript{3} Noemi Rotllan Vila,\textsuperscript{4} Natasha M. Girgis,\textsuperscript{5} Jianhua Liu,\textsuperscript{6} Viktoria Gusarova,\textsuperscript{7} Jesper Gromada,\textsuperscript{7} Ada Weinstock,\textsuperscript{1} Kathryn J. Moore,\textsuperscript{1} P'ng Loke,\textsuperscript{8} and Edward A. Fisher\textsuperscript{1}

\textsuperscript{1}Departments of Medicine (Cardiology) and Cell Biology, and the Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, New York, USA. \textsuperscript{2}Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA. \textsuperscript{3}Department of Biochemistry and Molecular Biology, Oregon State University Corvallis, Oregon, USA. \textsuperscript{4}Department of Vascular Biology and Therapeutics Program, and Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine and Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA. \textsuperscript{5}Constellation Pharmaceuticals, Cambridge, Massachusetts, USA. \textsuperscript{6}Department of Surgery, Mount Sinai School of Medicine, New York, New York, USA. \textsuperscript{7}Regeneron Pharmaceuticals, Tarrytown, New York, USA. \textsuperscript{8}Department of Microbiology, New York University School of Medicine, New York, New York, USA.

Atherosclerosis is a chronic inflammatory disease, and developing therapies to promote its regression is an important clinical goal. We previously established that atherosclerosis regression is characterized by an overall decrease in plaque macrophages and enrichment in markers of alternatively activated M2 macrophages. We have now investigated the origin and functional requirement for M2 macrophages in regression in normolipidemic mice that received transplants of atherosclerotic aortic segments. We compared plaque regression in WT normolipidemic recipients and those deficient in chemokine receptors necessary to recruit inflammatory Ly6\textsuperscript{Ch} (Ccr2\textsuperscript{−/−} or Cx3cr1\textsuperscript{−/−}) or patrolling Ly6\textsuperscript{C} (Ccr5\textsuperscript{−/−}) monocytes. Atherosclerotic plaques transplanted into WT or Ccr5\textsuperscript{−/−} recipients showed reduced macrophage content and increased M2 markers consistent with plaque regression, whereas plaques transplanted into Ccr2\textsuperscript{−/−} or Cx3cr1\textsuperscript{−/−} recipients lacked this regression signature. The requirement of recipient Ly6\textsuperscript{Ch} monocyte recruitment was confirmed in cell trafficking studies. Fate-mapping and single-cell RNA sequencing studies also showed that M2-like macrophages were derived from newly recruited monocytes. Furthermore, we used recipient mice deficient in STAT6 to demonstrate a requirement for this critical component of M2 polarization in atherosclerosis regression. Collectively, these results suggest that continued recruitment of Ly6\textsuperscript{Ch} inflammatory monocytes and their STAT6-dependent polarization to the M2 state are required for resolution of atherosclerotic inflammation and plaque regression.

Introduction

Despite major advances in treatment, atherosclerosis through its clinical sequelae, heart attack and stroke, is the leading cause of death worldwide. Regression of atherosclerosis is a vital goal in the quest to reduce cardiovascular risk, given that virtually all people by their fourth decade of life have established arterial plaques, some of which may ultimately become the culprit lesions causing clinical events.

To better understand the process of atherosclerosis regression, we and our collaborators have developed a number of surgical and non-surgical mouse models (1–4). In the surgical model, an APOE-deficient (Apoε\textsuperscript{−/−}) C57BL/6 mouse aortic arch segment with atherosclerotic plaques is transplanted into the abdominal aorta of a WT C57BL/6 recipient mouse. This sudden and sustained normalization of dyslipidemia leads to remarkably rapid decreases in both plaque size and the content of cells positive for the standard macrophage marker CD68 (5–8). Reductions in the same parameters have also been noted in other mouse models of atherosclerosis regression in which normalization of dyslipidemia was induced by non-surgical means (reviewed in ref. 9).

One influential classification of macrophages is based on the work of Saimon Gordon and Alberto Mantovani and their colleagues, who have broadly described M1 (classically activated) and M2 (alternatively activated) states (10, 11). In vitro, macrophages can polarize toward either the M1 or M2 state by treatment with IFN-γ and LPS, or IL-4 and IL-13, respectively. Notably, in regressing atherosclerotic plaques, we have observed that there is reduced expression of classical inflammatory genes characteristic of M1 macrophages, such as monocyte chemoattractant protein-1 (MCP-1), TNF-α, and iNOS, coincident with increased expression of genes encoding markers of alternatively activated, tissue-remodeling M2 macrophages, such as arginase 1 (ARG1), mannose receptor (MR, also known as CD206), and IL-10 in CD68\textsuperscript{+} cells (2, 3, 5, 12, 13). Importantly, the enrichment of plaque CD68\textsuperscript{+} cells with markers of the M2 phenotype, though initially discovered in the transplant model (5, 12), has been subsequently found in several different models of atherosclerosis regression (2–4), suggesting this represents a signature of plaque regression.

The mechanisms by which the macrophage phenotype changes from M1 to M2 in regressing plaques and whether this shift is...
required for regression remain unknown. Based on one study of macrophage phenotypes during the progression of atherosclerosis in Apoe<sup>−/−</sup> mice — in which serial immunohistological examinations showed that plaque macrophages have M2 phenotypes at the early stages of the disease but become M1 macrophages as the lesions advance (14) — it is possible that M1 macrophages in the plaques retain plasticity and reclaim characteristics of the original M2 phenotype in the regression environment. Alternatively, the M2 macrophages may be derived through the proliferation of a pool of tissue-resident macrophages (15) that originated from the yolk sac, as has previously been demonstrated in other tissues (16). Finally, M2 macrophages in regressing plaques may be derived from newly recruited monocytes.

Based on our earlier studies showing continued recruitment of circulating monocytes into regressing plaques (17), we prioritized testing this third hypothesis. We focused on two key questions: (a) If newly recruited monocytes become M2 macrophages, which circulating monocyte subset provided the new cells? (b) Is the conversion to the M2 phenotype required for plaque regression?

There are two major subsets of murine monocytes, and they are traditionally defined by the expression of different chemokine receptors: CCR2+CX3CR1+Ly6Chi and CCR2−CX3CR1−Ly6Clo monocytes. These subsets are characterized by distinct migratory and inflammatory properties (reviewed in ref. 16). The classical Ly6Clo monocytes efficiently infiltrate inflammatory sites, dominating the acute inflammatory response to pathogens, as well as the monocytosis and recruitment into progressing plaques in Apoe<sup>−/−</sup> mice (18, 19). They employ both CCR2 and CX3CR1 to enter atherosclerotic lesions and are thought to become M1 macrophages in most inflammatory sites (19–21). Thus, Ly6Clo cells are often termed “inflammatory monocytes.” In contrast, the nonclassical monocytes (CCR2 CX3CR1−Ly6Clo) do not express CCR2, but do express the highest levels of CX3CR1 (21). These monocytes patrol blood vessels and also accumulate at inflammatory sites, where they are thought to give rise to M2 macrophages (21). Because the Ly6Clo monocytes do not express CCR2, other chemokine receptors must be responsible for their recruitment to atherosclerotic plaques. Surprisingly, despite their high expression of CX3CR1, this chemokine receptor was dispensable for nonclassical monocyte recruitment, whereas CCR5 was not (19). Notably, the combined inhibition of CCR2, CX3CR1, and CCR5 essentially abolished atherosclerosis progression in hyperlipidemic mice, suggesting that recruitment of both subsets of circulating monocytes into plaques is required for their development (22).

To investigate the source of, and functional requirement for, M2 macrophages in atherosclerosis regression, we employed the aortic transplantation model and used recipient mice lacking the major receptors required for Ly6Clo and Ly6Clo monocyte recruitment into developing plaques (e.g., CCR2 and CCR5, respectively). We show herein that recruitment of recipient CCR2-dependent Ly6Clo monocytes is essential for atherosclerosis regression and the concurrent reduction in plaque macrophage content and enrichment in M2 macrophages. Notably, enrichment in the M2 phenotype and reduction in macrophage content were both markedly attenuated in regressing plaques when the STAT6 signaling pathway, known to be downstream from the M2-polarizing cytokines IL-4/IL-13 (23), was absent in recipient mouse circulating monocytes. Overall, these results indicate a previously unappreciated requirement for the recruitment of inflammatory Ly6Clo monocytes and their STAT6-dependent conversion to tissue-remodeling M2 macrophages in the regression of atherosclerosis.

Results

Deficiency of CCR2 or CX3CR1, but not CCR5, in aortic transplant recipients prevents plaque regression despite the reversal of dyslipidemia. At 4 weeks of age, Apoe<sup>−/−</sup> mice were fed a standard high-fat high cholesterol diet (“Western diet” [WD]) to exacerbate their hyperlipidemia so that they developed advanced atherosclerotic lesions by 16 weeks (baseline group). The aortic arches from these donor mice were then transplanted into Apoe<sup>−/−</sup>, WT, Ccr2<sup>−/−</sup>, Cx3cr1<sup>−/−</sup>, or Ccr5<sup>−/−</sup> mice maintained on a Chow diet, as illustrated in the experimental design in Figure 1A. In contrast to the hyperlipidemia of the Apoe<sup>−/−</sup> recipients, which led to atherosclerosis progression, the lipid-protein profiles showed that the WT and chemokine receptor–deficient mice were all normolipidemic, with total plasma cholesterol levels of ~90 mg/dl (vs. ~1,100 mg/dl in the Apoe<sup>−/−</sup> donors on WD and ~400 mg/dl in the Apoe<sup>−/−</sup> recipients on chow; data not shown).

As we previously reported (5, 6, 12, 24), plaque area as well as macrophage (CD68<sup>+</sup>) cells and neutral lipid (i.e., staining positive for Oil Red O) content in aortic arches transplanted into the regression environment of the WT mice were significantly decreased to ~50% of baseline by 5 days (Figure 1, B–E). Similarly, plaque, CD68<sup>+</sup>, and lipid areas decreased in the Ccr5<sup>−/−</sup> recipients to a level comparable to that observed in WT recipients (Figure 1, B–E), consistent with regression of atherosclerosis. However, transfer of aortic segments into Ccr2<sup>−/−</sup> or Cx3cr1<sup>−/−</sup> recipients did not lead to significantly decreased plaque area or CD68<sup>+</sup> cell content compared with baseline, despite plasma lipid-protein levels similar to those in WT recipients (Figure 1, B, C, and E). Furthermore, CCR2 or CX3CR1 deficiency in transplant recipients prevented the decrease in plaque neutral lipid content observed in the WT and Ccr5<sup>−/−</sup> recipients (Figure 1, D and E). These results indicate that CCR2 and CX3CR1, which mediate the recruitment of Ly6Clo monocytes into progressing plaques (19, 25–27), are essential for the regression of atherosclerosis. Furthermore, although CCR5 contributes to atherosclerosis progression by recruiting Ly6Clo monocytes (22), this chemokine receptor, and by extension recruitment of Ly6Clo monocytes, is not required for atherosclerosis regression.

Deficiency of CCR2 or CX3CR1, but not CCR5, in transplant recipients prevents the accumulation of M2 macrophages in regressing plaques. In various models of atherosclerosis regression, an enrichment of M2 macrophage markers accompanies the change in plaque content of CD68<sup>+</sup> cells (2, 4, 5, 12). To determine whether the chemokine receptors CCR2, CX3CR1, and CCR5 contribute to the enrichment of M2 macrophages and the reduction of the M1 inflammatory phenotype in regressing plaques, we transplanted aortic segments into the recipient mouse groups as outlined in Figure 1A and examined the expression of the M1 macrophage marker MCP-1 and the M2 markers MR and ARG1 by immunohistochemical staining. As shown in Figure 2, A–C, the MR- and ARG1-positive areas were significantly increased, while MCP-1 staining was decreased, in plaques transferred to normolipidemic WT (as expected) and Ccr5<sup>−/−</sup> recipient mice compared with those from Apoe<sup>−/−</sup> recipient mice. In contrast, the MCP-1<sup>+</sup>, MR<sup>+</sup>, and...
Our findings are in agreement with recent reports that Ly6Chi inflammatory monocytes recruited to allergic skin, schistosome granulomas, or injured myocardium subsequently acquired the M2 phenotype (20, 28–31). Acute inhibition of CCR2 prevents plaque regression and suppresses enrichment in the M2 macrophage phenotype. CCR2 is critical for both egress of Ly6C\text{hi} monocytes from bone marrow and for their entry into progressing atherosclerotic plaques; indeed, Ccr2\text{–/–} mice have reduced numbers of circulating monocytes and, when crossed to mouse models of atherosclerosis, have smaller plaques (22, 25, 26). As the reduction of circulating monocytes in Ccr2\text{–/–} mice may confound the interpretation of the aortic transplant experiments, we complemented this genetic approach with studies using a small molecule inhibitor of CCR2, which does not alter the total number of circulating monocytes or their subsets.

ARG1\textsuperscript{+} areas did not change significantly in plaques transplanted into Ccr2\textsuperscript{–/–} or Cx3cr1\textsuperscript{–/–} recipient mice. Indeed, only a small proportion of plaque CD68\textsuperscript{+} cells in the Ccr2\textsuperscript{–/–} and Cx3cr1\textsuperscript{–/–} recipients expressed MR or ARG1, while a significant majority of plaque CD68\textsuperscript{+} cells in WT and Ccr5\textsuperscript{–/–} recipients were MR\textsuperscript{+} and ARG1\textsuperscript{+} (Figure 2, A–C). The results suggest that the recruitment of recipient monocytes through CCR2 and CX3CR1 is crucial not only for atherosclerosis regression, but also for the accumulation of M2 macrophages. These results, taken with the data in Figure 1, make the possibility that the conversion of M1 cells in the donor plaques is a significant source of M2 macrophages unlikely. Rather, they overwhelmingly appear to be derived from active recruitment of recipient monocytes from the Ly6C\textsuperscript{hi} subset. Although M2 macrophages have been proposed to arise from either the Ly6C\textsuperscript{lo} subset (21) or from proliferation of tissue macrophages derived from the yolk sac (16), our findings are in agreement with recent reports that Ly6C\textsuperscript{hi} inflammatory monocytes recruited to allergic skin, schistosome granulomas, or injured myocardium subsequently acquired the M2 phenotype (20, 28–31).

Acute inhibition of CCR2 prevents plaque regression and suppresses enrichment in the M2 macrophage phenotype. CCR2 is critical for both egress of Ly6C\textsuperscript{hi} monocytes from bone marrow and for their entry into progressing atherosclerotic plaques; indeed, Ccr2\textsuperscript{–/–} mice have reduced numbers of circulating monocytes and, when crossed to mouse models of atherosclerosis, have smaller plaques (22, 25, 26). As the reduction of circulating monocytes in Ccr2\textsuperscript{–/–} mice may confound the interpretation of the aortic transplant experiments, we complemented this genetic approach with studies using a small molecule inhibitor of CCR2, which does not alter the total number of circulating monocytes or their subsets in
monocytes, we used two different labeling methods to track their recruitment into plaques. Using EdU (5-ethynyl-2′-deoxyuridine) to specifically label Ly6Chi (32–34) circulating monocytes (design shown in Figure 4A, labeling efficiency shown in Figure 4, B and C), we observed a significant reduction (relative to WT recipients) in EdU-labeled monocytes in plaques transplanted into Ccr2–/–, but not Ccr5–/–, mice (Figure 4D). This confirms that deficiency of CCR2 in recipient mice resulted in decreased recruitment of Ly6Chi monocytes into plaques in a regression environment. Second, using fluorescent latex beads to specifically label circulating Ly6Clo (8, 17, 19) monocytes (Figure 4, E and F), we observed that relative to WT recipients, there was a reduction (\(P = 0.05\)) in bead-labeled cells in plaques transplanted into Ccr5–/–, but not Ccr2–/–, recipient mice (Figure 4G). There were no significant differences in macrophage proliferation or apoptosis between the plaques transplanted into WT, Ccr2–/–, and Ccr5–/– recipients, as measured by staining for Ki67 (Figure 4H) and cleaved caspase 3 (Figure 4I).

Assessment of monocyte trafficking shows Ly6C\(^{hi}\) monocyte recruitment is key to impaired regression in Ccr2–/– mice. To extend the results with the inhibitor and to demonstrate that the impaired regression of plaques transplanted into Ccr2–/– recipient mice was specifically due to the reduced recruitment of the Ly6C\(^{hi}\) subset of monocytes, we used two different labeling methods to track their recruitment into plaques. Using EdU (5-ethynyl-2′-deoxyuridine) to specifically label Ly6C\(^{hi}\) (32–34) circulating monocytes (design shown in Figure 4A, labeling efficiency shown in Figure 4, B and C), we observed a significant reduction (relative to WT recipients) in EdU-labeled monocytes in plaques transplanted into Ccr2–/–, but not Ccr5–/–, mice (Figure 4D). This confirms that deficiency of CCR2 in recipient mice resulted in decreased recruitment of Ly6C\(^{hi}\) monocytes into plaques in a regression environment. Second, using fluorescent latex beads to specifically label circulating Ly6C\(^{lo}\) (8, 17, 19) monocytes (Figure 4, E and F), we observed that relative to WT recipients, there was a reduction (\(P = 0.05\)) in bead-labeled cells in plaques transplanted into Ccr5–/–, but not Ccr2–/–, recipient mice (Figure 4G). There were no significant differences in macrophage proliferation or apoptosis between the plaques transplanted into WT, Ccr2–/–, and Ccr5–/– recipients, as measured by staining for Ki67 (Figure 4H) and cleaved caspase 3 (Figure 4I),
respectively. As plaques transplanted into Ccr5−/− recipient mice show regression similar to those in WT mice, despite the lack of recruitment Ly6Clo monocytes, this suggests that this monocyte population is not required for the promotion of atherosclerosis regression. Furthermore, the recruitment of Ly6C^hi monocytes into plaques is intact in Ccr2−/− recipient mice, yet regression fails to occur, indicating that Ly6Clo monocyte–derived cells cannot replace Ly6C^hi monocytes in promoting plaque regression.

**M2 macrophages originate from newly recruited cells from recipient mice.** Though there is concurrent recruitment of recipient monocytes and enrichment in plaque CD68+ cells with macrophage M2 characteristics, this does not definitely establish a direct link between these two findings. To demonstrate, using multiple approaches, that recipient mouse monocytes are indeed the source of M2 macrophages in regressing plaques, the following experiments were performed. First, we performed fate mapping studies using the pan-leukocyte marker CD45, which has two isoforms, CD45.1 and CD45.2; these can be distinguished from each other using the pan-leukocyte marker CD45, which has two isoforms, CD45.1 and CD45.2; these can be distinguished from each other using monoclonal antibodies (outline in Figure 5A) (35). Starting at 4 weeks of age, CD45.1 Apoe−/− mice were fed a WD for 14 weeks to induce the development of advanced atherosclerotic lesions (baseline group). The aortic arches were then transplanted into WT, Ccr2−/−, or Ccr5−/− mice on a CD45.2 background maintained on a chow diet. We omitted the Cx3cr1−/− group, because the previous results in Figures 1 and 2 were essentially the same as in Ccr2−/− mice or in mice treated with the CCR2 inhibitor.

Consistent with Figure 1, the plaques in aortic arches transplanted into Ccr2−/− mice showed impaired regression compared with those transplanted into WT and Ccr5−/− mice (data not shown). There was also a significant reduction in CD45.1+ donor-derived cells in plaques transplanted into WT and Ccr5−/−, but not Ccr2−/− mice (Figure 5, B and C). Conversely, there was significant accumulation of CD45.2+ newly recruited recipient-derived cells, compared with baseline, in plaques transplanted into WT and Ccr5−/−, but not Ccr2−/− mice (Figure 5, B and C). As shown in Figure 5D, ~80% of the MR+ cells in the plaques in the WT recipient group were of CD45.2 (recipient-derived) origin. Overall, the data are consistent with the impaired regression in Ccr2−/− mice being due to less recruitment of recipient monocytes, and that the newly recruited monocytes become polarized overwhelmingly to the M2 macrophage state.

Next, we transplanted aortic arches from Apoe−/− mice that were fed the WD for 16 weeks (baseline group) into CD68-GFP transgenic mice, a model recently introduced for tracking CD68+ macrophage–derived cells, including in atherosclerosis (outline in Figure 5E) (36, 37). After 5 days, the transplanted arches were excised and enzymatically digested to release cells from the plaques. Using surface marker labeling and flow cytometry, we measured the content of M2 macrophages by gating on CD45+CD-11b+F4/80+MR+ cells. Notably, we found that 73.9% ± 6.5% (n = 3) of the M2 macrophages in regressing plaques were CD68-GFP+ (representative analysis shown in Figure 5F), indicating that the majority of those macrophages originated from the recipient, and not donor, mice.

To extend these findings, we also isolated CD45+CD-11b+F4/80+ macrophages from aortic arches from mice in baseline and regression groups subjected to aortic digestion and FACS. Single macrophages were then captured in a Fluidigm C1 instrument for single-cell RNA sequencing (RNA-seq) analysis. As outlined in Figure 5G, only newly recruited cells from the WT recipient mice will express Apoe mRNA, thus allowing us to use it as a marker for macrophage origin during regression. Compared with baseline, a large proportion of aortic macrophages from regressing plaque samples expressed both Apoe and Cdl206 (encoding MR), as well as Apoe and Arg1 mRNAs (Figure 5H). This shows at a single-cell level that M2 macrophages in regressing plaques originate from newly recruited monocytes. Together, these data from three different approaches strongly support that there is recruitment of monocytes in transplant recipient mice and that they are the sources of the M2 macrophages in regressing plaques.

**Figure 3. Effect of CCR2 inhibition on atherosclerosis regression and M2 macrophage enrichment.** Effect of CCR2 inhibitor on the frequency of (A) total monocytes and (B) Ly6C^hi and Ly6C^lo monocyte subsets in the blood of recipient mice (vehicle, n = 2, and CCR2 inhibitor, n = 3). (C–E) Quantification of (C) lesion area, (D) the macrophage marker CD68, and (E) MR and MCP-1 staining in aortic arch plaques from Apoe−/− mice on 16-week WD (BL; n = 6) or 3 days after transplant into WT mice (regression environment) that were untreated (n = 6) or treated with vehicle (n = 5) or a CCR2 inhibitor (n = 6). For C and D: ***P < 0.001 compared with BL using 1-way ANOVA with Dunnett’s multiple comparisons testing. For E, ***P < 0.0001, CCR2 inhibitor group compared with vehicle group using unpaired t testing.
Deficiency of STAT6 in the monocytes of aortic transplant recipients prevents the accumulation of M2 macrophages and impairs plaque regression. To determine whether the M2 enrichment in regressing plaques requires the classical IL-4/IL-13/STAT6 signaling pathway (23) in the newly recruited recipient monocytes, we transplanted aortic arches from Apoe−/− mice into normolipidemic Stat6−/− recipient mice. Notably, our findings in Stat6−/− recipient mice recapitulate those in Ccr2−/− and Cx3cr1−/− recipient mice, as well as in mice that underwent acute CCR2 inhibition, in that plaques showed no significant decrease in lesion area, CD68+ content, or Oil Red O neutral lipid area (Figure 6, A–C, and E). Furthermore, lack of STAT6 in transplant recipients prevented...
Figure 5. CCR2 deficiency in recipient leukocytes impairs their recruitment to atherosclerotic plaques, where they normally display M2 characteristics. (A) Schematic of CD45.1 (donor) to CD45.2 (recipient) aortic transplantation experiments with (B) quantification of immuno-histochemical staining of CD45.1 and CD45.2 in aortic arch plaques from Apoe<sup>−/−</sup> mice on 14-week WD (BL; n = 7) or 5 days after transplant into WT mice (Regr; n = 8), or chemokine receptor–KO recipient mice (Ccr2<sup>−/−</sup> or Ccr5<sup>−/−</sup>; n = 8); ***P < 0.001 for the indicated comparisons group using 1-way ANOVA with Dunnett’s multiple comparisons testing. (C) Representative images of aortic plaques stained for CD45.1 and CD45.2, imaged at ×40 quantification. (D) Quantification of immunohistochemical staining of MR<sup>+</sup> with CD45.2 or CD45.1 showing 80.72% ± 3.597% MR<sup>+</sup> cells originate from recipient CD45.2 mice (n = 3) with representative images at ×40 magnification. (E) Schematic of transplantation experiment using CD68-GFP reporter mice to mark recipient monocytes/macrophages. (F) Representative flow cytometry plots showing that a majority of CD45<sup>+</sup>CD11b<sup>+</sup>F4/80<sup>+</sup>MR<sup>+</sup> macrophages are GFP<sup>+</sup> in aortic arches harvested 5 days after transplantation (n = 3). (G) Schematic of transplantation experiment for single cell RNA-seq experiments, with (H) scatter plots showing, at a single-cell level, that cells expressing high levels of Apoe (i.e., recipient) are also positive for high levels of M2 macrophage markers Cd206 (MR) and Arg1 in the population of Cd11b<sup>+</sup>F4/80<sup>+</sup> macrophages isolated from aortic arches 3 days after transplantation.
support a model in which atherosclerosis regression is mediated by newly recruited Ly6C\textsuperscript{hi} monocytes that polarize to M2 macrophages in a STAT6-dependent manner.

Discussion

Atherosclerosis is a chronic inflammatory disease that develops in the setting of hyperlipidemia, with progression a consequence of the failure to resolve inflammation (38). Using a number of mouse models of atherosclerosis regression, including the aortic arch transplant used in the present study, we have previously shown that aggressive lipid lowering promotes the resolution of plaque

Figure 6. Lack of STAT6 in recipient mice prevents M2 macrophage enrichment of plaques and impairs atherosclerosis regression. Analysis of aortic arch plaques from mice 3 days after transplantation into Apoe\textsuperscript{−/−} (Progr; n = 6), WT (Regr; n = 6), or Stat6\textsuperscript{−/−} (n = 6) mice for (A) lesion area, (B) immunohistochemical staining for the macrophage marker CD68, (C) Oil red O staining for neutral lipid, and (D) immunohistochemical staining for the M1 macrophage marker MCP-1 and the M2 macrophage marker MR (CD206). **P < 0.001 compared with Apoe\textsuperscript{−/−} progression group using 1-way ANOVA with Dunnett’s multiple comparisons testing. (E) Representative images of aortic plaques stained for CD68, Oil red O (ORO), MCP-1, and CD206, imaged at ×40 magnification. (F) qRT-PCR analysis of mRNA expression of newly recruited monocyte-derived macrophage marker (ApoE), CD206 (M2) (Arg1 and Cd206), and M1 (Ccl2) macrophage markers in CD68\textsuperscript{+} cells laser captured from the aortic arch plaques 3 days after transplant into WT and Stat6\textsuperscript{−/−} recipient mice (n = 4–7 per group). *P < 0.05 using unpaired t testing.
inflammation, which is characterized by a decreased content of macrophages and an increase in the level of markers of the M2 state (2, 4, 5, 12). We now extend these findings to show that plaque regression and the attendant resolution of inflammation surprisingly require the recruitment of new monocytes, which assume the characteristics of M2 macrophages. Furthermore, contrary to the prevailing paradigm (16), the newly recruited monocytes are drawn from the Ly6C<sup>hi</sup> circulating subset, generally considered to be "inflammation-prone" precursors of M1 macrophages.

These findings are based on a number of experimental approaches, which include aortic transplantation of atherosclerotic aortae into recipient mice with normolipidemia and deficiencies of various chemokine receptors; monocyte/macrophage trafficking methods; the administration of an inhibitor of CCR2-mediated Ly6C<sup>hi</sup> monocyte recruitment; the differentiation of donor from recipient cells by CD45.1/45.2 fate mapping; determination of CD68-driven GFP expression; and single-cell RNA-seq of plaque macrophages. Together, these data provide a strong foundation for our major conclusion, namely that atherosclerosis regression after lipid lowering is dependent on the recruitment of Ly6C<sup>hi</sup> monocytes and their polarization toward the M2 phenotype. Furthermore, the data also strongly suggest that Ly6C<sup>hi</sup> monocyte–derived cells cannot replace the required Ly6C<sup>lo</sup> monocytes in promoting plaque regression. While we have reported the enrichment in plaques of the M2 phenotype in a number of mouse models of atherosclerosis regression (2–4, 5, 12), we recognize that the present results are based on a specific aortic transplantation model. Whether they explain the M2 phenotypic enrichment more generally in other murine models of atherosclerosis regression or apply to the clinical setting will require additional investigation.

The characteristic rapid reversal of hyperlipidemia in mouse atherosclerosis regression models is likely to reduce the continuous stimulation of the plaque inflammatory response by atherogenic lipoproteins, but clearly is not sufficient for the resolution of inflammation. Based on our results, M2 enrichment must also occur, and how the change in lipoprotein environment causes this to happen also remains to be determined. Our finding that it depends on STAT6–dependent signaling in the newly recruited monocytes suggests that local factors in the regressing plaque stimulate this signaling pathway. STAT6 is activated by two key cytokines, IL-4 and IL-13. However, which of these cytokines is the main player, as well as their cellular source(s), in promoting plaque regression is unclear.

A number of potential sources of these cytokines exist, including Th2 lymphocytes, which can accumulate in plaques (39). Indeed, we have shown that adaptive CD4<sup>+</sup> T cells are required for maintenance of M2 macrophages during chronic helminth infection (40). Another possibility is suggested by the finding that during acute allergic skin inflammation, basophils are a source of the IL-4 that polarizes newly recruited Ly6C<sup>hi</sup> monocytes to M2 macrophages (28). Furthermore, eosinophils have been identified as a source of IL-4/IL-13 for M2 macrophage polarization in adipose tissue under steady-state conditions and during acute helminth infection, and invariant NKT (NKT) cells provide IL-4 to promote monocyte differentiation to M2 macrophages in experimental autoimmune encephalomyelitis (EAE) (41). Which of these immune cell subtypes is important for M2 polarization signaling in atherosclerosis regression is being actively investigated by our laboratory.

Though many questions remain, the present results provide insights into the dynamic nature of the inflammatory process and the role of Ly6C<sup>hi</sup> monocytes in plaques. These cells were previously thought to contribute only to plaque progression and inflammation, but are now shown here to be important in regression and inflammation resolution. One clinically relevant insight raised by our studies is that strategies that promote the accumulation of M2 macrophages in atherosclerotic lesions may be a promising approach toward promoting plaque regression, consistent with recent studies in mice in which treatment with IL-13- or IL-4–based therapy was protective against atherosclerosis progression (42, 43).

**Methods**

**Animals and aortic transplantation.** The aortic arch transplantation model has been described previously (5, 6, 8, 12, 17, 24). Briefly, a donor arch from an atherosclerotic mouse was interpositioned with the abdominal aorta in the recipient mouse, and blood flow was directed through the graft. The donor Apoe<sup>−/−</sup> (B6.129P2-Apoe<sup>tm1Unc</sup>/J) mice, in either a CD45.1 (Apoc<sup>−/−</sup> crossed with B6.129P2–Ptprc<sup>−/−</sup>Peprc<sup>−/−</sup>Boy/J) or CD45.2 background, were weaned at 4 weeks onto a 21% fat, 0.3% cholesterol WD (Dyets Inc.) for 14–16 weeks. Mice were then divided into one group (pre-transplant) for baseline analyses and another group to be donors of aortic arch segments. The recipients were WT (C57BL/6), CD68-GFP reporter (C57BL/6-Tg(CD68-EGFP)1Drg/J), Apoc<sup>−/−</sup>, Ccr2<sup>−/−</sup> (B6.129S4-Ccr2<sup>tm1Kuz</sup>/J), Cx3cr1<sup>−/−</sup> (B6.129P2-Cx3cr1<sup>tm1Ifc</sup>/J), Ccr5<sup>−/−</sup> (B6.129P2-Ccr5<sup>tm1Litt</sup>/J), or Stat6<sup>−/−</sup> (B6.129S2(C)-Stat6<sup>tm1Dym</sup>/J) mice on a CD45.2 background (purchased from The Jackson Laboratory). All recipient mice were 20 weeks old and maintained on standard chow diet, and were sacrificed 3 or 5 days after transplantation. In some experiments, mice were administered an inhibitor of CCR2 (CCX417), which was provided by ChemoCentrx. 10 mg/ml stock of CCX417 was used at a dose of 5 ml/kg subcutaneously once a day, as instructed by ChemoCentrx, and administered for 48 hours before and 72 hours after the transplantation.

**Single-cell RNA-seq cell isolation and flow cytometry analysis.** CD45<sup>+</sup>CD11b<sup>+</sup>F4/80<sup>+</sup> macrophages were isolated using the BD FACS Aria IIu SORP from pre-transplant baseline and grafted arches from WT recipient mice (regression) that were removed after perfusion of cold PBS and enzymatic digestion as described in ref. 44. Cell surface markers were labeled with the following antibodies: CD45 PerCpCy5.5 (BioLegend, catalog 103132), CD11b AF700 (BioLegend, catalog 141122), and F4/80 PerCy7 (BioLegend, catalog 123114). Single cells were captured and processed on a Fluidigm C1 instrument in collaboration with Regeneron Pharmaceuticals as described in ref. 45.

For analysis of cells isolated from grafted arches from CD68-GFP reporter mice, samples were processed as described above, and flow cytometry was conducted on a BD LSRII UV. Cell surface markers were labeled with CD45 PerCpCy5.5 (BioLegend, catalog 103132), CD11b BV650 (BioLegend, catalog 101225), F4/80 PeCy7 (BioLegend, catalog 123114), and MR/CD206 APC (BioLegend, catalog 141712).

**Single-cell RNA-seq analysis.** Single-cell RNA-seq reads were mapped to the reference mouse genome (GRCm38), including multiple mapped reads, using ArrayStudio. Estimated counts of reads that mapped within each of 24,475 RefSeq genes, taking into account read-mapping uncertainty, were obtained using the RNA-Seq by Expectation Maximization (RSEM) algorithm (46) in ArrayStudio (OmicSoft). We carried out all sub-
sequent RNA-seq analysis steps in the R statistical computing environment (version 3.2.1; https://www.r-project.org/). We excluded from further analysis all genes for which the count did not exceed zero in at least two samples. For the remaining 16,294 genes, we rounded the expression counts to the nearest integer and then adjusted the count values on a per-sample basis using DESeq2 (http://bioconductor.org/packages/release/bioc/html/DESeq2.html) normalization, with size factors based on the sample-wise geometric means of the counts for genes with nonzero counts in each sample. We then quantile-normalized (47) the count data in order to adjust for batch effects. For the global unsupervised two-dimensional visualization of the RNA-seq data, we transformed the normalized count matrix by adding one to each entry and then log$_2$ transforming. We used multidimensional scaling (MDS) (48) with $n = 2$ dimensions (including only genes for which the normalized count was 50 or greater in at least one sample) in order to obtain an unsupervised two-dimensional visualization of the log$_2$-transformed gene expression data on a sample-specific basis. We further eliminated any sample from downstream analysis if its sum of log$_2$ counts was not at least 1,200. The above sample assignment basis. We further eliminated any sample from downstream analysis if its

Monocyte subset labeling. Mice were injected intraperitoneally with 1 mg/mouse EdU (Life Technologies, catalog E10187) to label the Ly6C$^+$ subset of monocytes. EdU incorporation into circulating monocytes was detecting using the Click-IT Plus EdU Pacific Blue Flow Cytometry Assay Kit (Life Technologies, catalog C10636) and in plaque tissue using the Click-IT Plus Edu Alexa Fluor 647 Imaging Kit (Life Technologies, catalog C10640). Mice were injected retro-orbitally with green fluorescent latex beads to label Ly6C$^+$ monocytes. Their incorporation into circulating monocytes was detected and number of beads/section assessed as described in refs. 8, 17, 19. Circulating monocytes were detected by flow cytometry using surface markers CD45 PE/Cy7 (BioLegend, catalog 103114), CD115 PE (BioLegend, catalog 135506) or APC (BioLegend, catalog 135510), and Ly6C APC (BioLegend, catalog 108412) or PerCP Cy5.5 (BD Bioscience, catalog 560525).

Statistics. Data are expressed as mean ± SEM. Data were typically analyzed by 1-way ANOVA (GraphPad Prism 7), with Dunnett’s multiple comparisons testing when there were 3 or more groups. Data involving comparisons between 2 groups were analyzed using unpaired t testing (GraphPad Prism 7). $P \leq 0.05$ was considered significant.

Study approval. These studies were performed in strict accordance with the recommendations in the NIH Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011). The Institutional Animal Care and Use Committee of the New York University School of Medicine reviewed and approved the protocol.

Author contributions. KR, YV, KJM, PL, and EAF designed experiments. KR, YV, and EAF wrote the draft of the manuscript, followed by editing by KJM and PL. KR, YV, NRV, NMG, and AW performed experiments. JL performed transplant surgeries on all mouse groups. VG and JG coordinated and performed the single-cell RNA-seq experiments. SAR analyzed single-cell RNA-seq data. AL performed transplant surgeries on all mouse groups. VG and JG coordinated and performed the single-cell RNA-seq experiments. SAR analyzed single-cell RNA-seq data.

Acknowledgments. This work was supported by NIH grant HL084312 (EAF, PL, and KJM); NIH training grant T32HL098129 (YV); and Comisionado para Universidades e Investigación (CUR), DIUE, Generalitat de Catalunya and Fulbright program (NRV). KR was supported by NIH training grants T32GM007308 and T32AI00853, and NIH fellowship F30HL131183. PL was supported by grants from the NIH (AI093811 and AI094166), and NMG was supported by NIH fellowship F32AI02502 and training grant T32AI007180. SAR was supported by NSF grants 1557605-DMS and 1553728-DBI, Medical Research Foundation of Oregon New Investigator Grant, PhRMA Foundation Informatics Grant, and Oregon State University Division of Health Sciences Interdisciplinary Research Grant. We also acknowledge Yi Wei, Qi Su, and Yurong Xin of Regeneron Pharmaceuticals for their work on the single-cell RNA-seq experiments, as well as Yaritzy Astudillo, Yoscar Ogando, and Sheila George of the Fisher laboratory for their technical contributions.
Address correspondence to: Edward A. Fisher, Department of Medicine, Division of Cardiology/Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, Smilow, Room 704, 522 First Avenue, New York, New York 10016, USA. Phone: 212.263.6631; Email: edward.fisher@nyumc.org. Or to: P’ng Loke, Department of Microbiology, New York University School of Medicine, Alexandria Center for Life Sciences, AW Room 314, 430 East 29th Street, New York, New York 10016, USA. Phone: 646.501.4649; Email: png.loke@nyumc.org.


